Zobrazeno 1 - 7
of 7
pro vyhledávání: '"David Edward Gilham"'
Autor:
Gray Kueberuwa, Milena Kalaitsidou, Eleanor Cheadle, Robert Edward Hawkins, David Edward Gilham
Publikováno v:
Molecular Therapy: Oncolytics, Vol 8, Iss , Pp 41-51 (2018)
Chimeric antigen receptor (CAR) T cell therapy represents a significant advancement in cancer therapy. Larger studies have shown ∼90% complete remission rates against chemoresistant and/or refractory CD19+ leukemia or lymphoma. Effective CAR T cell
Externí odkaz:
https://doaj.org/article/63995466918d4f859e877d75298134f7
Autor:
Gray Kueberuwa, Milena Kalaitsidou, Eleanor Cheadle, Robert Edward Hawkins, David Edward Gilham
Publikováno v:
Molecular Therapy Oncolytics
Kueberuwa, G, Kalaitsidou, M, Cheadle, E, Hawkins, R & Gilham, D 2017, ' CD19 CAR T-cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity ', Molecular therapy oncolytics . https://doi.org/10.1016/j.omto.2017.12.003
Molecular Therapy: Oncolytics, Vol 8, Iss, Pp 41-51 (2018)
Kueberuwa, G, Kalaitsidou, M, Cheadle, E, Hawkins, R & Gilham, D 2017, ' CD19 CAR T-cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity ', Molecular therapy oncolytics . https://doi.org/10.1016/j.omto.2017.12.003
Molecular Therapy: Oncolytics, Vol 8, Iss, Pp 41-51 (2018)
Chimeric antigen receptor (CAR) T cell therapy represents a significant advancement in cancer therapy. Larger studies have shown ∼90% complete remission rates against chemoresistant and/or refractory CD19+ leukemia or lymphoma. Effective CAR T cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::52b60be6bb388afcb0d896f65c14d1f5
http://europepmc.org/articles/PMC5772011
http://europepmc.org/articles/PMC5772011
Autor:
Gray, Kueberuwa, Hannah, Gornall, Erik Marcelo, Alcantar-Orozco, Deborah, Bouvier, Zainul Abedin, Kapacee, Robert Edward, Hawkins, David Edward, Gilham
Publikováno v:
Journal for Immunotherapy of Cancer
Background Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate with favourable clinical outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4e15693c763d20f3d2883dd79dc1b44d
https://pubmed.ncbi.nlm.nih.gov/28239467
https://pubmed.ncbi.nlm.nih.gov/28239467
Publikováno v:
Immunotherapy (1750743X); May2015, Vol. 7 Issue 5, p487-497, 11p
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 07/14/2021.
Autor:
Zhang, Wenlong
Publikováno v:
Immunotherapy (1750743X); Mar2016, Vol. 8 Issue 3, p245-247, 3p
Autor:
Wenlong Zhang
Publikováno v:
Immunotherapy. 8(3)
A letter in response to: Milena Kalaitsidou, Gray Kueberuwa, Antje Schütt & David Edward Gilham. CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy 7(5), 487–497 (2015).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6328f27398cfb43fa3fbcc2752f008a
https://pubmed.ncbi.nlm.nih.gov/26065475
https://pubmed.ncbi.nlm.nih.gov/26065475